A new two-column 225Ac/213Bi generator was developed specifically for using 225Ac containing an impurity of long lived 227Ac. The parent 225Ac was retained on the first Actinide Resin column, while 213Bi was accumulated on the second column filled with AG MP-50 resin via continuous elution and decay of intermediate 221Fr. The 213Bi accumulation was realized in circulation mode which allowed a compact generator design. It was demonstrated that 213Bi could be quickly and effectively extracted from AG MP-50 in form of complexes with various chelating agents including DTPA and DOTA. The performance of the generator presented and a conventional single-column generator on the base of AG MP-50 was tested and both generators were loaded with 225Ac ...
An externally controllable sealed isotope generator has been proposed for radiation education activi...
An improved chemical strategy for processing of the generator produced 68Ga was developed based on p...
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated t...
The potential of applying 213Bi in targeted alpha therapy (TAT) of cancer and infectious diseases ha...
The alpha emitters 225Ac and 213Bi are promising therapeutic radionuclides for application in target...
Bi-213 is a radioactive isotope being evaluated for a variety of cancer therapies. Tissue-specific m...
An improved ‘2Sr—'2Rb generator system, based on the complexing ion-exchange resin Chelex-1...
Abstract only availableBismuth 213 is an alpha radioimmunotherapeutic agent used in cancer treatment...
PurposeWe demonstrate cyclotron production of high-quality 225Ac using an electroplated 226Ra target...
Introduction: Alpha-emitting radionuclides have gained considerable attention as payloads for cancer...
Yttrium-90 (Y-90) has attracted much research attention in targeted radionuclide therapy because its...
Interest in the use of alpha radiation emitters in radio immunotherapy is due to the high linear ene...
An ion-exchange method is presented to separate the radioisotope 227Pa from a Th target after bombar...
The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in...
The generator nuclide 62Cu (T1/2 = 9.7 min) is a suitable positron emitter for repeated PET study wi...
An externally controllable sealed isotope generator has been proposed for radiation education activi...
An improved chemical strategy for processing of the generator produced 68Ga was developed based on p...
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated t...
The potential of applying 213Bi in targeted alpha therapy (TAT) of cancer and infectious diseases ha...
The alpha emitters 225Ac and 213Bi are promising therapeutic radionuclides for application in target...
Bi-213 is a radioactive isotope being evaluated for a variety of cancer therapies. Tissue-specific m...
An improved ‘2Sr—'2Rb generator system, based on the complexing ion-exchange resin Chelex-1...
Abstract only availableBismuth 213 is an alpha radioimmunotherapeutic agent used in cancer treatment...
PurposeWe demonstrate cyclotron production of high-quality 225Ac using an electroplated 226Ra target...
Introduction: Alpha-emitting radionuclides have gained considerable attention as payloads for cancer...
Yttrium-90 (Y-90) has attracted much research attention in targeted radionuclide therapy because its...
Interest in the use of alpha radiation emitters in radio immunotherapy is due to the high linear ene...
An ion-exchange method is presented to separate the radioisotope 227Pa from a Th target after bombar...
The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in...
The generator nuclide 62Cu (T1/2 = 9.7 min) is a suitable positron emitter for repeated PET study wi...
An externally controllable sealed isotope generator has been proposed for radiation education activi...
An improved chemical strategy for processing of the generator produced 68Ga was developed based on p...
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated t...